NASDAQ$VCYT
Veracyte Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Veracyte reported Q4 2025, revenue of $140.6M, net income of $41.1M, diluted EPS of $0.51.
For Q4 2025, Veracyte reported revenue of $140.6M, net income of $41.1M, diluted EPS was $0.51, adjusted diluted EPS was $0.53 per the quarterly earnings release and SEC filing.
- Revenue $140.6M.
- Net income $41.1M.
- Diluted EPS $0.51.
- Adjusted EPS $0.53.
Headline financials
Revenue & EPS history
Veracyte · Revenue · Quarterly
$141M
Revenue by segment
Veracyte · $90.1M total across 3 segments · Q3 2023
- Testing Revenue$82M+27.0%91.0%
- Biopharmaceutical and Other$4.08M-47.1%4.5%
- Product Revenue$4.02M+21.3%4.5%
Forward guidance
Veracyte outlook reflects management commentary on growth, costs, and capital in the filing.
Tailwinds
- Liquidity and balance sheet discussed.
- Core operating trends in MD&A.
Headwinds
- Macro and competitive pressure.
- One-time items may affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+1.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+5.4%
Avg return
30 days after
50%
23 / 46 earnings
Positive
+28.8%
Q2 2024
Best reaction
-22.4%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.9% | +20.4% | +47.7% | |
| Q4 2025 | +8.4% | -1.8% | -16.0% | |
| Q3 2025 | -9.4% | -7.3% | -3.1% | |
| Q1 2025 | +1.3% | -5.0% | -11.0% | |
| Q4 2024 | -15.0% | -11.7% | -21.0% | |
| Q3 2024 | +3.9% | +8.2% | +22.8% | |
| Q2 2024 | +28.8% | +39.4% | +41.8% | |
| Q1 2024 | -3.8% | +2.2% | +2.3% | |
| Q4 2023 | -9.6% | -3.7% | -14.1% | |
| Q3 2023 | -2.3% | -6.3% | +5.6% | |
| Q2 2023 | +7.9% | +1.5% | +2.2% | |
| Q1 2023 | +8.2% | +6.7% | +24.2% | |
| Q4 2022 | +5.3% | +6.6% | -3.3% | |
| Q3 2022 | +17.3% | +19.8% | +41.1% | |
| Q2 2022 | -3.0% | +8.1% | -23.3% | |
| Q1 2022 | +4.0% | -14.6% | -15.6% | |
| Q4 2021 | +4.1% | -8.1% | +6.8% | |
| Q3 2021 | -9.5% | -5.2% | -22.4% | |
| Q2 2021 | +13.0% | +13.1% | +21.0% | |
| Q1 2021 | -10.1% | -17.6% | -19.9% | |
| Q4 2020 | -6.5% | -15.5% | -30.4% | |
| Q3 2020 | +10.3% | +23.9% | +58.9% | |
| Q2 2020 | +18.2% | +6.7% | +9.4% | |
| Q1 2020 | -0.1% | -2.6% | -4.4% | |
| Q4 2019 | -2.3% | +3.7% | +3.3% | |
| Q3 2019 | -15.6% | -19.0% | -1.8% | |
| Q2 2019 | -2.8% | -13.8% | -7.3% | |
| Q1 2019 | +9.1% | +6.6% | +8.5% | |
| Q4 2018 | +9.1% | +2.5% | +20.1% | |
| Q3 2018 | +20.4% | +47.9% | +30.6% | |
| Q2 2018 | +8.6% | +4.0% | +15.6% | |
| Q1 2018 | -2.1% | +0.5% | +26.2% | |
| Q4 2017 | +1.0% | +0.3% | -6.7% | |
| Q3 2017 | -22.4% | -24.8% | -24.8% | |
| Q2 2017 | -2.1% | -1.3% | -4.8% | |
| Q1 2017 | -0.5% | -8.1% | -0.5% | |
| Q4 2016 | +12.0% | +17.8% | +18.5% | |
| Q3 2016 | -1.9% | +5.3% | +19.2% | |
| Q2 2016 | -0.2% | +1.2% | +14.4% | |
| Q1 2016 | +1.1% | — | — | |
| Q4 2015 | -8.8% | — | — | |
| Q3 2015 | -1.0% | — | — | |
| Q2 2015 | -7.9% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -10.9% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro